Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection? (Q35207318)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942682%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

review article

1 reference

title

Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942682%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942682%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Mona Loutfy

1 reference

7 November 2019

language of work or name

1 reference

1 January 2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942682%20AND%20SRC:MED&resulttype=core&format=json

Journal of the International Association of Providers of AIDS Care

7 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942682%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942682%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942682%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

95-103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942682%20AND%20SRC:MED&resulttype=core&format=json

Structured treatment interruptions in antiretroviral management of HIV-1.

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Structured treatment interruptions for the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Effect of the Human Immunodeficiency Virus Epidemic on Mortality from Opportunistic Infections in the United States in 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Decline in deaths from AIDS due to new antiretrovirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Persistence of HIV-1 Transcription in Peripheral-Blood Mononuclear Cells in Patients Receiving Potent Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

HIV protease inhibitor-related lipodystrophy syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Factors affecting adherence to antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Discontinuation of potent antiretroviral therapy: predictive value of and impact on CD4 cell counts and HIV RNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Immune control of HIV-1 after early treatment of acute infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Warning: antiretroviral treatment interruption could lead to an increased risk of HIV transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Control of HIV despite the Discontinuation of Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Resuppression of virus load after interruption in treatment with nevirapine and 2 nucleoside reverse-transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Skewed maturation of memory HIV-specific CD8 T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Selective depletion in HIV infection of T cells that bear specific T cell receptor V beta sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Resistance Profiles in Patients with Viral Rebound on Potent Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F154510970200100304

10.1177/154510970200100304

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942682%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12942682%20AND%20SRC:MED&resulttype=core&format=json